

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * AISLING CAPITAL III LP (Last) (First) (Middle) 888 SEVENTH AVE., 12TH FLOOR, (Street) NEW YORK, NY 10106 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/29/2016	3. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	508,565	\$ (1)	D (2)	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
AISLING CAPITAL III LP 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X		
Aisling Capital Partners III LP 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X		
Aisling Capital Partners III LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X		
ELMS STEVE				

C/O AISLING CAPITAL LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X		
SCHIFF ANDREW N C/O AISLING CAPITAL LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X		
Purcell Dennis J C/O AISLING CAPITAL LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X		

Signatures

See Signatures on Exhibit 99.1		06/29/2016
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Series B Preferred Stock is convertible into Common Stock on a 3.75-for-one basis into the number of shares shown in column 3 at (1) any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

(2) The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

FORM 3 JOINT FILER INFORMATION

Names of Joint Filers:

Aisling Capital III, LP
Aisling Capital Partners III, LP
Aisling Capital Partners III LLC
Steve Elms
Andrew N. Schiff, M.D.
Dennis J. Purcell

Address of Joint Filers:

c/o Aisling Capital Partners LLC
888 Seventh Avenue, 12th Floor
New York, NY 10106

Designated Filer: Aisling Capital III, LP

Issuer and Ticker Symbol: Syros Pharmaceuticals, Inc. [SYRS]

Date of Event: June 29, 2016

Signatures of Joint Filers:

AISLING CAPITAL III, LP

By: Aisling Capital Partners III, LP
General Partner

By: Aisling Capital Partners III LLC
General Partner

By: /s/ Lloyd Appel
Name: Lloyd Appel
Title: CFO

**AISLING CAPITAL PARTNERS III,
LP**

By: Aisling Capital Partners III LLC
General Partner

By: /s/ Lloyd Appel
Name: Lloyd Appel
Title: CFO

**AISLING CAPITAL PARTNERS III
LLC**

By: /s/ Lloyd Appel
Name: Lloyd Appel
Title: CFO

/s/ Steve Elms
Steve Elms

/s/ Andrew Schiff
Andrew Schiff

/s/ Dennis Purcell
Dennis Purcell
